| 新辅助化疗在非手术治疗宫颈癌患者中的临床应用价值 |
| |
| 引用本文： | 李金砖,陈绍俊. 新辅助化疗在非手术治疗宫颈癌患者中的临床应用价值[J]. 现代肿瘤医学, 2019, 0(24): 4420-4424. DOI: 10.3969/j.issn.1672-4992.2019.24.023 |
| |
| 作者姓名： | 李金砖 陈绍俊 |
| |
| 作者单位： | 广西医科大学第四附属医院柳州市工人医院肿瘤科，广西 柳州 545005 |
| |
| 摘 要： | 目的:探讨新辅助化疗在非手术治疗宫颈癌患者中的临床应用价值。方法:85例非手术治疗的Ⅰb2期、Ⅱa2期及Ⅱb-Ⅳa期宫颈癌患者，分为新辅助组49例、无新辅助组36例，全部患者均接受盆腔三维适形放疗序贯后装放疗，A点总剂量85 Gy，放疗期间予顺铂40 mg/m2同步化疗，每周一次，共4~6个周期；新辅助组患者在放疗开始前予“紫杉醇175 mg/m2+卡铂AUC=5”新辅助化疗1个周期，化疗后三周开始同步放化疗序贯后装放疗。比较两组患者的近期客观疗效、总生存期和无进展生存期。结果:新辅助组客观缓解率及疾病控制率均为98.0%，无新辅助组均为97.2%，差异无统计学意义（P=0.826）。新辅助组与无新辅助组的1、3、5年OS率依次为100%、82%、62%与97%、78%、51%，差异无统计学意义（P=0.700）。新辅助组与无新辅助组的1、3、5年PFS率依次为96%、81%、61%与97%、78%、51%，差异无统计学意义（P=0.791）。结论:对于采用同步放化疗序贯后装放疗的Ⅰb2期、Ⅱa2期及Ⅱb-Ⅳa期宫颈癌患者，放疗前是否应用紫杉醇+卡铂新辅助化疗在患者的近期客观疗效、总生存期和无进展生存期方面未见有意义结果。
|
| 关 键 词： | 宫颈癌 紫杉醇 卡铂 新辅助化疗 同步放化疗 |
Clinical effect of neoadjuvant chemotherapy on non-surgical cervical cancer |
| |
| Li Jinzhuan,Chen Shaojun. Clinical effect of neoadjuvant chemotherapy on non-surgical cervical cancer[J]. Journal of Modern Oncology, 2019, 0(24): 4420-4424. DOI: 10.3969/j.issn.1672-4992.2019.24.023 |
| |
| Authors: | Li Jinzhuan Chen Shaojun |
| |
| Affiliation: | Department of Oncology,Liuzhou Worker's Hospital,the Fourth Hospital Affiliated to Guangxi Medical University,Guangxi Liuzhou 545005,China. |
| |
| Abstract: | Objective:To study the clinical effect of neoadjuvant chemotherapy of paclitaxel combined with carboplatin on non-surgical cervical cancer.Methods:Eighty-five cases of non-surgical cervical cancer patients on phase Ⅰb2,Ⅱa2 and Ⅱb-Ⅳa were divided into fourty-nine patients in neoadjuvant chemotherapy (NACT) group and thirty-six patients in non-NACT group.All the patients were treated with three-dimensional conformal radiotherapy (3D-CRT) in the pelvic sequential intracavitary radiotherapy with a total dose of 85 Gy at A point and cisplatin for 40 mg/m2 per week during radiotherapy with 4~6 cycles.The patients in NACT group were given one cycle of paclitaxel for 175 mg/m2 combined with carboplatin for AUC=5 in three weeks before radiotherapy.The curative effect,overall survival (OS) and progression-free survival (PFS) between two groups were compared.Results:The objective remission rate (ORR) and disease control rate (DCR) in NACT group were 98.0% and in non-NACT group were 97.2%,and the difference was not statistically significant (P=0.826).The OS rates of one-year,three-year and five-year in NACT group were 100%,82%,62%,in non-NACT group were 97%,78% and 51%,with no statistical significance (P=0.700).The PFS rates of one-year,three-year and five-year in NACT group were 96%,81%,61% and 97%,78%,51% in non-NACT group,with no statistical significance (P=0.791).Conclusion:To all of non-surgical cervical cancer patients on phase Ⅰb2,Ⅱa2 and Ⅱb-Ⅳa who were treated with concurrent chemoradiotherapy in the pelvic sequential intracavitary radiotherapy,there was no statistical significance in the curative effect,OS and PFS no matter whether in chemotherapy of paclitaxel combined with carboplatin before radiotherapy. |
| |
| Keywords: | cervical cancer paclitaxel carboplatin neoadjuvant chemotherapy concurrent chemoradiotherapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
|
